NextCell Pharma presents historical quarterly figures

March 3, 2026

At the Extraordinary General Meeting of NextCell Pharma AB (publ) (“NextCell” or the “Company”) held on 21 August 2025, it was resolved that the Company shall change its financial year from a broken financial year September–August to a calendar year January–December. The Company’s first full financial year in accordance with the calendar year will be 2026. To facilitate historical comparisons and enhance transparency for future reports that will follow the calendar year structure, the Company is today publishing financial information for the five most recent comparative quarters.

During the extended financial year 2024/2025, the following interim reports were published:

Q1: September–November 2024, published 30 January 2025
Q2: December 2024–February 2025 (accumulated September 2024–February 2025), published 25 April 2025
Q3: February 2025–April 2025 (accumulated September 2024–April 2025), published 24 July 2025
Q4: May 2025–August 2025 (accumulated September 2024–August 2025), published 30 October 2025
Year-end report: October 2025–December 2025 (accumulated September 2024–December 2025), published 26 February 2026

The Year-end Report 2025 for the period September 2024–December 2025 was NextCell Pharma’s first interim report prepared in accordance with the calendar year structure. The quarter reported was October–December 2025 (accumulated September 2024–December 2025). The Q1 2026 report for the period January–March 2026 will be NextCell Pharma’s first interim report under the ordinary calendar year structure and will be published on 28th of May 2026.

The summary of the comparison quarters contains no new information, other than a new quarterly breakdown based on the structure of the calendar year, derived from previously published data.

The report is available on the company's website.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Eric Gustafsson, CFO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com

Websites:
NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark: www.cellaviva.dk
QVance AB: www.qvance.se

LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye Sweden AB is the company´s Certified Adviser.

About NextCell Pharma AB
NextCell Pharma is a clinical-stage cell therapy company developing ProTrans, a patent-protected platform based on allogeneic mesenchymal stromal cells (MSCs) from umbilical cord tissue. Using a proprietary selection algorithm, ProTrans delivers optimised cell tailored to specific indications. In type 1 diabetes, a single infusion has been shown to preserve insulin production and delay disease progression for at least five years. A Phase III trial is planned to commence upon securing a commercial partner. ProTrans is also being evaluated for other autoimmune and inflammatory conditions. NextCell’s subsidiaries include Cellaviva, Scandinavia’s largest private stem cell bank, and QVance, the Nordic region’s first dedicated provider of quality services for developers of advanced therapies.

Download attachment Read full press release on Cision (external link)

2026-02-17

NextCell Participating in JETRO’s Japan Entry Acceleration Program

NextCell Pharma AB (“NextCell” or the “Company”) announces its participation in the Japan Entry Acceleration Program (“JEAP”) in regenerative medicine, an international accelerator initiative organized and funded by JETRO. NextCell is communicating its participation in connection with the Company’s current presence in Tokyo, where program activities and meetings with Japanese industrial, regulatory and financial stakeholders are now taking place.

Read more Read more

2026-02-03

Seven-year follow-up data from ProTrans-Repeat demonstrate sustained disease-modifying effects of ProTrans in type 1 diabetes

NextCell Pharma AB (“NextCell” or the “Company”) today announces long-term follow-up data from the ProTrans-Repeat study showing sustained preservation of endogenous insulin production in patients with newly diagnosed type 1 diabetes. The data extends to approximately 6 years after the last ProTrans infusion, corresponding to 7 to 7.5 years since the first infusion.

Read more Read more

2026-01-21

NextCell provides strategic update on focused market progression, highlighting Hong Kong as gateway to the Chinese market

NextCell Pharma AB (“NextCell” or the “Company”) provides a strategic update on its focused market progression strategy, aimed at accelerating value creation by advancing ProTrans™ in adult patients, where NextCell already has a strong clinical foundation, while simultaneously strengthening the company’s global partnering position. This approach builds on NextCell’s original development strategy and is designed to create multiple independent value drivers for the company.

Read more Read more

2026-01-21

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NEXTCELL PHARMA AB (PUBL)

The shareholders of NextCell Pharma AB (publ), reg. no. 556965-8361, (the "Company") are hereby invited to attend an extraordinary general meeting on Tuesday, 10th of February 2026, at 10:00 CET at Novum-huset, floor 6 (lift E), Hälsovägen 7, Huddinge. Registration for the meeting will commence at 09.30 CET.

Read more Read more

2026-01-21

NextCell decides to propose a directed share issue of SEK 15 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, HONG KONG, JAPAN, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. The Board of Directors of NextCell Pharma AB (“NextCell” or the “Company”) has resolved to propose to the extraordinary general meeting (the “Extraordinary General Meeting”) to resolve on a directed share issue comprising a total of 15,000,000 shares to a number of strategic investors at a subscription price of SEK 1.00 per share (the “Directed Issue”). Participating investors include both new investors and a number of larger existing shareholders. The Extraordinary General Meeting is planned to be held on Tuesday, 10 February 2026. Notice of the Extraordinary General Meeting will be announced separately.

Read more Read more

2026-01-15

Six-year data demonstrate a durable disease-modifying effect of ProTrans in type 1 diabetes

NextCell Pharma AB (“NextCell” or the “Company”) today announces that six-year follow-up data indicate that a single infusion of ProTrans provides a long-lasting and clinically relevant preservation of endogenous insulin production in patients with newly-diagnosed type 1 diabetes. Patients treated with ProTrans continue to exhibit clinically relevant levels of stimulated C-peptide well beyond expected levels as seen with the natural course of the disease.

Read more Read more

2025-12-09

NextCell in Swedish Life Science Delegation to Hong Kong

NextCell Pharma AB (“NextCell” or “the Company”) is participating in the Swedish life science delegation to Hong Kong on 10–12 December 2025, organised by the Hong Kong Chamber of Commerce in Sweden and the Hong Kong Biotechnology Organisation (HKBIO). The delegation brings together leading Swedish companies to deepen collaborations in research, clinical development, industrial production, and investment in Hong Kong and the Greater Bay Area (GBA).

Read more Read more

2025-12-02

NextCell initiates collaboration with OptiCell – strengthening its cell-handling operations

NextCell Pharma AB (“NextCell” or “the Company”) has entered into a collaboration agreement with OptiCell Solutions AB (“OptiCell”) regarding the handling, freezing, storage, and transport of cell products used for research and development. The collaboration enables NextCell to further leverage its existing infrastructure and expertise in advanced cell handling, also beyond its own clinical projects.

Read more Read more